CTC Bio Inc

CTC Bio Inc maintains a debt-to-equity ratio of 0.59 and a current ratio of 1.38, indicating moderate leverage and acceptable short-term liquidity. The company's price-to-book ratio of 1.2 and price-to-tangible-book ratio of 1.2 suggest market valuation is in line with its equity base. Free cash flow of 9.01 billion KRW supports operational flexibility, though capital expenditures of -786.53 million KRW indicate minimal reinvestment in physical assets. Profitability metrics show a return on equity of 4.46% and return on assets of 2.26%, both below the typical thresholds for pharmaceutical firms, which often exceed 10% ROE and 5% ROA. Gross margin of 40.6% (50.32 billion KRW gross profit on 123.77 billion KRW revenue) is in line with industry norms, but operating margin of 5.07% (6.28 billion KRW operating income) suggests pressure from cost structures or pricing. The company operates through two segments: Human Pharmaceuticals and Animal Pharmaceuticals. Revenue concentration data is not disclosed, but the dual-segment model provides diversification across therapeutic and agricultural markets. Domestic and overseas markets are both served, though geographic exposure is not quantified in the latest financials. Outlook for the current fiscal year shows a revenue trajectory that is not explicitly quantified, but the company's free cash flow and operating cash flow of 4.38 billion KRW suggest capacity for growth initiatives. Historical revenue growth is not provided, but the company's operating income margin of 5.07% implies a need for cost optimization or pricing power to drive future expansion. Risk assessment highlights a medium liquidity risk due to negative net cash after subtracting total debt, and a low dilution risk based on current share structure. No dilution adjustments are applied in the valuation, and the company's shares outstanding remain unchanged between basic and diluted measures. Recent events include no disclosed filings or transcripts in the latest data, but the company's capital structure and operating cash flow suggest a stable, though not aggressive, financial position.